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Abstract. Metabolic reprogramming is one of the hallmarks 
of cancer and can be targeted by therapeutic agents. We 
previously reported that cathelicidin-related or modified anti-
microbial peptides, such as FF/CAP18, have antiproliferative 
effects on the squamous cell carcinoma cell line SAS-H1, 
and the colon carcinoma cell line HCT116. Although anti-
microbial peptides have potential use in the development of 
new therapeutic strategies, their effects on the metabolism 
of cancer cells are poorly understood. Here, we investigated 
changes in the levels of metabolites in HCT116 cells caused by 
FF/CAP18, via capillary electrophoresis time-of-flight mass 
spectrometry (CE-TOFMS). Analysis of the 177 intracellular 
metabolites and 113 metabolites in conditioned medium that 
were detected by CE-TOFMS, revealed dramatic changes in 
the metabolic profile of HCT116 cells after treatment with 
FF/CAP18. The metabolic profile showed that the levels of 
most metabolites in the major metabolic pathways supported 
the rapid proliferation of cancer cells. Purine metabolism, 
glycolysis, and the TCA cycle, were altered in FF/CAP18-
treated cells in a dose-dependent manner. Our present study 
provides mechanistic insights into the anticancer effects of 
antimicrobial peptides that show great potential as new thera-
pies for colon cancer.
Introduction
Cancer is described as one of the major world health problems 
(1). Colorectal cancer is the third most common malignancy 
worldwide and nearly 1.4 million new cases were reported in 
2012 (2). Accumulation of oncogenes and tumor suppressor 
gene mutations can contribute to cancer development. High-
throughput DNA sequencing data suggested that thousands of 
point mutations, translocations, amplifications, and deletions 
may contribute to cancer development, and that the mutational 
range can differ, even among tumors with identical histo-
pathology (3). Therefore, any therapeutic strategy designed 
to target individual signaling molecules has limitations in 
improving current survival rates and novel strategies are 
needed.
Metabolic reprogramming is one of the hallmarks of 
cancer, in addition to gene mutation (4). To support rapid cell 
division and the process of tumor progression, cancer cells 
need to generate energy by reprogramming their metabolism. It 
is well established that cancer cells can generate ATP through 
glycolysis rather than oxidative phosphorylation, even in the 
presence of oxygen (the Warburg effect) (5). Characteristic 
metabolic reprogramming, including the Warburg effect, is 
consistently seen in various cancers, despite numerous gene 
mutations, indicating that cancer cell metabolic pathways 
could be useful therapeutic targets. Hirayama et al (6) and 
Soga et al (7) reported metabolic profiling of human colon and 
stomach cancers, and compared the levels of metabolites in 
tumor and normal tissues using capillary electrophoresis time-
of-flight mass spectrometry (CE-TOFMS). Recently, the use 
of metabolome analysis has remarkably developed in various 
research fields, such as clinical research, cell biology, and plant 
studies (8-10). Metabolomics is the final step in the ‘omics’ 
cascade, of genomics, transcriptomics, and proteomics, and 
can provide global information on low-molecular-weight-
metabolites (11,12). Metabolome analysis could reveal the 
influences on cancer metabolism of anticancer agents, and 
accelerate biomarker discovery based on the determination 
of metabolomic differences between normal and cancerous 
tissue.
Members of the cathelicidin family of antimicrobial 
peptides are endogenous factors playing key roles in cancer 
regulation (13). Human cathelicidin antimicrobial protein, 
hCAP18, is the only member of the cathelicidin family in 
human cells; its C-terminal domain, LL-37, is released by 
proteolytic cleavage, and shows various effects, such as 
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antibacterial, antiviral, wound-healing, and immunoregula-
tory effects (14,15). LL-37 is expressed in epithelial cells of 
a number of organs (16). A previous study showed that the 
expression of LL-37 was markedly downregulated in human 
colon cancer tissue, whereas exogenous LL-37 induced apop-
totic cell death in cultured colon cancer cells. In addition, 
cathelicidin-deficient mice exhibited increased susceptibility 
to azoxymethane-induced colon carcinogenesis (17).
We previously reported that a 27-residue analog of the 
LL-37 peptide, FF/CAP18, induced apoptotic cell death, via 
mitochondrial membrane depolarization and DNA fragmenta-
tion, in the oral squamous cell carcinoma cell line SAS-H1, 
(18) and the colon carcinoma cell line HCT116 (19). Although 
these findings suggest that antimicrobial peptides have 
possible anticancer effects and could be targeted for new 
therapeutic strategies, the full mechanisms of their suppressive 
effects on metabolic pathways are still largely unknown. In the 
present study, using metabolome analysis by CE-TOFMS, we 
identified changes in energy metabolism caused by FF/CAP18 
during the process of apoptosis in human colon cancer cells.
Materials and methods
Cell culture and peptides. The human HCT116 colon carci-
noma-derived cell line was provided by Dr Bert Vogelstein 
(Johns Hopkins University, Baltimore, MD, USA). The cells 
were maintained in Dulbecco's modified Eagle's medium 
(Nacalai Tesque, Kyoto, Japan) containing 10% fetal bovine 
serum (Invitrogen, Carlsbad, CA, USA) and a 5% antibiotic-
antimycotic mixed stock solution (Nacalai Tesque) at 37˚C 
and 5% CO2. Before being used for experiments, cells were 
routinely maintained under exponential-proliferation condi-
tions. The cells were treated with a 0.25% trypsin-EDTA 
solution (Nacalai Tesque) to dislodge them at each passage.
The primary structure of LL-37 is represented in a single 
amino acid code as follows: LLGDFFRKSKEKIGKEFKRIV 
QRIKDFLRNLVPRTES. To enhance antimicrobial activity, 
FF/CAP18 was designed by the replacement of a glutamic acid 
residue and a lysine residue with phenylalanine at positions 11 
and 20, respectively, of the 27mer (FRKSKEKIGKEFKRI 
VQRIKDFLRNLV) which resulted from the removal of the 
first and last five amino acids of LL-37 (20). FF/CAP18 (FRKS 
KEKIGKFFKRIVQRIFDFLRNLV) was synthesized by the 
method previously described (18).
Detection of apoptosis using a combined Annexin V-7-amino-
actinomycin D (7-AAD) assay. One feature of the early 
stages of apoptosis is externalization of plasma membrane 
phosphatidylserine to the cell surface. Owing to this process, 
cells showing the early stages of apoptosis can be identified 
via binding of Annexin V, which has high affinity for phos-
phatidylserine, whereas cells in the late stage of apoptosis or 
necrosis show no affinity for Annexin V. Furthermore, 7-AAD, 
a fluorescent DNA-binding agent that intercalates between 
cytosine and guanine, also allows the distinction of cells that 
are alive, dead, or in the early or late stages of apoptosis. The 
combination of these two reagents is available as a powerful 
apoptosis-detection tool in the Muse® Annexin V and Dead 
Cell assay kit (Merck Millipore, Darmstadt, Germany). After 
incubation with FF/CAP18 for 96 h, cells were trypsinized, 
transferred into 1.5-ml microtubes, and subjected to centrifu-
gation at 800 x g for 5 min. Cell pellets were resuspended in 
100 µl of fresh medium, and the Muse Annexin V and Dead 
Cell Dye assay kit reagent was added (100 µl to each tube) with 
mixing. After incubation for 20 min at room temperature, cells 
were applied to a Muse Cell Analyzer (Merck Millipore).
Metabolome extraction. Samples of cells and of conditioned 
medium were obtained 96 h after administration of FF/CAP18. 
Cell samples were washed twice with a 5% solution of mannitol 
and covered with methanol. Cells were harvested after addi-
tion of the internal standard solution (Human Metabolome 
Technologies, Tsuruoka, Japan), and subjected to centrifugation 
for 5 min at 2,300 x g, 4˚C. The aqueous layers were collected 
into ultrafiltration units (EMD Millipore, Billerica, MA, USA) 
and subjected to centrifugation for 2.5 h at 9,600 x g, 4˚C. The 
conditioned medium from cell cultures was directly collected 
to prepare medium samples. The sampled medium was mixed 
with the internal standard solution, and subjected to centrifu-
gation for 2.5 h at 9,600 x g, 4˚C.
Measurement of metabolites. CE-TOFMS was carried 
out using an Agilent 7100 CE system equipped with an 
Agilent 6210 TOFMS system, Agilent 1100 high-performance 
liquid chromatography system with isocratic pump, Agilent 
G1603A CE-Mass Spectrometry (MS) Adapter kit, and Agilent 
G1607A CE Electrospray Ionization-MS Sprayer kit (Agilent 
Technologies, Waldbronn, Germany). The systems were 
controlled using the Agilent G2201AA ChemStation software, 
version B.03.01, for CE (Agilent Technologies). Metabolites 
were analyzed using a fused silica capillary (50 µm internal 
diameter x 80 cm length), with commercial electropho-
resis buffer (Solution ID: H3301-1001 for cation analysis 
and I3302-1023 for anion analysis; Human Metabolome 
Technologies) as the electrolyte. The sample was injected at 
a pressure of 50 mbar for 10 sec (equivalent to ~10 nl) in the 
cation analysis, and at 50 mbar for 25 sec (equivalent to ~25 nl) 
in the anion analysis. The spectrometer was scanned across a 
mass-to-charge ratio (m/z) of 50-1,000. Other conditions were 
as previously described (21-23).
The peaks detected by CE-TOFMS were extracted using 
MasterHands automatic integration software (Keio University, 
Tsuruoka, Japan) in order to obtain peak information including 
m/z, migration time (MT), and peak area (24). Signal peaks 
corresponding to isotopomers, adduct ions, and other product 
ions of known metabolites were excluded, and the remaining 
peaks were annotated with putative metabolites from the 
Human Metabolome Technologies metabolite database, based 
on their MT and m/z values. The tolerance range for the peak 
annotation was configured at ±0.5 min for MT and ±10 parts 
per million for m/z. In addition, peak areas were normalized to 
those of the internal standards, and the resultant relative area 
values were then further normalized to the sample amount.
Hierarchical cluster analysis (HCA) and principal compo-
nent analysis (PCA) were carried out using the proprietary 
software, PeakStat and SampleStat, respectively (Human 
Metabolome Technologies). Detected metabolites were plotted 
on metabolic pathway maps using the Visualization and 
Analysis of Networks containing Experimental Data software 
(25).
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Statistical analysis. In the combined Annexin V binding-
7-AAD staining assay, the ratio of cells at each apoptotic stage 
was expressed as the mean ± standard deviation. Statistical 
differences were tested with Student's t-test. The statistical 
significance of differences in the 177 intracellular metabolites 
and the 113 metabolites detected in conditioned medium, 
between treated and untreated cells, was determined using 
Welch's t-test. A value of P<0.05 was considered significant.
Results
Apoptosis detection using the Annexin V-7-AAD assay. 
Combined Annexin V and 7-AAD reactivity allowed classifi-
cation of cells into four groups, as follows: early apoptotic cells 
[Annexin V (+) and 7-AAD (-)], late apoptotic or dead cells 
[Annexin V (+) and 7-AAD (+)], dead cells [Annexin V (-) and 
7-AAD (+)], and live cells [Annexin V (-) and 7-AAD (-)]; see 
the scatter plots in Fig. 1A. Treatment of HCT116 cells with 
FF/CAP18 at 10 µg/ml induced high affinity for Annexin V, 
as shown by the right shift of the scatter plot compared with 
that of non-treated cells, indicating early apoptosis (Fig. 1A, 
middle panel). On the other hand, FF/CAP18 treatment at 
40 µg/ml increased the number of cells that were positive for 
Annexin V (+) and 7-AAD (+), indicating that a high dose of 
FF/CAP18 induced apoptotic cell death in HCT116 cells. The 
ratio of HCT116 cells at each stage of apoptosis after treatment 
with the two different doses of FF/CAP18 is summarized in 
Fig. 1B. The percentage of live cells decreased significantly in 
a dose-dependent manner (Fig. 1B). The percentage of cells in 
early apoptosis, however, significantly increased with 10 µg/ml 
FF/CAP18 treatment, whereas, the percentage of late apop-
totic and dead cells only increased with 40 µg/ml treatment 
(Fig. 1B). From these results, we concluded that early-stage 
apoptosis was induced by a comparatively low dose (10 µg/ml) 
of FF/CAP18, whereas high-dose treatment (40 µg/ml) could 
cause late-stage apoptosis and cell death.
Heat map and PCA representation of metabolome data 
from HCT116 cells. The 177 intracellular metabolites and 
113 metabolites in conditioned medium were detected as 
peaks by CE-TOFMS, and mapped onto metabolic pathways 
for ease of viewing, as shown in Fig. 2 (cells) and Fig. 3 
(conditioned medium). Overall trends of the intracellular 
metabolomic changes in HCT116 cells treated with FF/CAP18 
and non-treated cells were analyzed by Euclidean-distance-
based HCA, and the results are presented as a heat map 
(Fig. 4). The metabolomic profile of HCT116 cells treated with 
10 µg/ml FF/CAP18 showed high values for the metabolites in 
Figure 1. Detection of apoptosis of HCT116 cells after treatment with FF/CAP18. Cells were treated with 10 or 40 µg/ml FF/CAP18 for 96 h and subjected to 
the combined Annexin V binding-7-AAD staining assay. (A) Representative results of the assay carried out with non-treated HCT116 cells (left panel), and 
with HCT116 cells treated with FF/CAP18 at 10 µg/ml (middle panel) or 40 µg/ml (right panel). Based on the reactivity with Annexin V and the intensity of the 
7-AAD fluorescence, cells can be classified into four categories: dead, live, early apoptosis and late apoptosis/dead. Triplicate experiments were conducted and 
representative results are shown. (B) The percentage of live cells (left panel), cells in early apoptosis (middle panel) and cells in late apoptosis or dead (right 
panel). Triplicate samples were used to obtain the mean and standard deviation. The asterisks indicate statistical significance. *P<0.05.
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Figure 2. Metabolome data map of all metabolic pathways in HCT116 cells. Each bar represents the relative amount of a metabolite for non-treatment (blue) 
and treatment with FF/CAP18 at 10 µg/ml (red) or 40 µg/ml (green). All metabolite data are shown as the mean of triplicate samples ± standard deviation.
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Figure 3. Metabolome data map of all metabolic pathways for conditioned medium. Each bar represents the relative amount of a metabolite for control medium 
(blue), conditioned medium after culture of HCT116 cells (red) and conditioned medium after culture of HCT116 cells treated with FF/CAP18 at 10 µg/ml 
(green) or 40 µg/ml (yellow). All metabolite data are shown as the mean of triplicate samples ± standard deviation.
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cluster 2, including amino acids, and tricarboxylic acid (TCA) 
cycle intermediates. In contrast, the metabolomic profile of 
HCT116 cells treated with 40 µg/ml FF/CAP18 was reversed 
in comparison to the profile for treatment with 10 µg/ml 
FF/CAP18. We also confirmed that the metabolomic profiles 
of HCT116 cells treated with FF/CAP18 at 10 or 40 µg/ml 
were reversed for metabolites in cluster 1, including nucleo-
tides and nucleosides. These trends were made even clearer 
from the results of the PCA of metabolome data for HCT116 
cells treated with FF/CAP18 (Fig. 5). The concentration of 
FF/CAP18 was reflected in principal component 1; principal 
component 2 demonstrated the difference between treat-
ment and non-treatment of cells with FF/CAP18. Therefore, 
treatment with FF/CAP18 exerted a dramatic change on the 
metabolism of HCT116 cells, and that change depended on the 
concentration of FF/CAP18.
Purine metabolism. Purine metabolism is an important 
pathway in order to supply nucleotides, such as 2'-deoxy-
adenosine triphosphate and 2'-deoxyguanosine triphosphate, 
for aggressive DNA synthesis in cancer cells. Fig. 6 shows 
the metabolic pathway of purine metabolism. The levels of 
adenosine triphosphate (ATP) and guanosine triphosphate 
(GTP) measured in HCT116 cells treated with FF/CAP18 at 
10 µg/ml (dark grey bar) were higher than in non-treated cells 
(black bar); simultaneously, a slight increase was detected 
in the levels of adenosine diphosphate (ADP), adenosine 
monophosphate (AMP), guanosine monophosphate (GMP), 
and guanosine diphosphate (GDP). In contrast, in HCT116 
cells treated with FF/CAP18 at 40 µg/ml (pale grey bar), 
there was a substantial decrease in the levels of ATP and GTP, 
whereas the levels of ADP, AMP, GMP, and GDP showed 
marked increases. These results suggest a high-energy status 
in HCT116 cells treated with the low dose (10 µg/ml) of 
FF/CAP18. However, HCT116 cells treated with the high 
dose of FF/CAP18 (40 µg/ml) fall into an energy-depleted 
status compared with non-treated and low-dose-treated cells. 
We could also confirm the presence of derivatives of purine, 
including adenine, hypoxanthine, and guanine, in HCT116 
cells treated with a high dose of FF/CAP18. Additionally, 
increased uric acid was detected in conditioned medium 
sampled after culturing HCT116 cells with a high dose of 
FF/CAP18 (Fig. 6); uric acid is the final product of purine 
metabolism, and these data indicate that treatment of HCT116 
cells with a high dose of FF/CAP18 facilitates the degradation 
of purine metabolites.
Glycolysis and the pentose phosphate pathway (PPP). 
Glycolysis is the key pathway for cancer cells to generate 
the energy that is required to support rapid cell division and 
cancer progression. We mapped the glycolysis pathway and 
a metabolic pathway branching from glycolysis, the PPP, as 
shown in Fig. 7. The levels of glucose 6-phosphate (G6P) 
and frucutose 6-phosphate (F6P) were increased after treat-
ment with FF/CAP18, in a dose-dependent manner. The 
level of fructose 1,6-bisphosphate (FBP), however, tended to 
be lower in cells treated with 10 µg/ml FF/CAP18 than in 
non-treated cells, and FBP was not detectable in cells treated 
with FF/CAP18 at 40 µg/ml. Downstream metabolites, such 
as 3-phosphoglycerate, phosphoenolpyruvate, pyruvic acid 
and lactic acid similarly showed downregulation. Pyruvic 
acid and lactic acid in conditioned medium also showed a 
slight decline in level in HCT116 cells treated with FF/CAP18 
(Fig. 7).
The PPP metabolites ribulose 5-phosphate (Ru5P), ribose 
5-phosphate (R5P), and sedoheptose 7-phosphate (S7P) were 
Figure 4. Euclidean-distance-based heat map of metabolites in non-treated 
HCT116 cells (left), and HCT116 cells treated with FF/CAP18 at 10 µg/ml 
(middle) or 40 µg/ml (right). The color scale from green to red indicates low 
to high correlation, respectively. Hierarchical cluster analysis was carried out 
using the proprietary software, PeakStat.
Figure 5. Principal component analysis (PCA) plot of metabolome analysis 
data that characterizes the trends exhibited by the expression profiles of 
non-treated HCT116 cells (blue), HCT116 cells treated with FF/CAP18 at 
10 µg/ml (red) and HCT116 cells treated with FF/CAP18 at 40 µg/ml (green). 
The x-axis shows the distance of PC1 and the y-axis shows the distance of 
PC2 in the scatter plot. PCA was carried out using the proprietary software, 
SampleStat.
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upregulated in a dose-dependent manner, whereas 6-phospho-
gluconate and xylurose 5-phosphate were not detected. These 
data indicate that glycolysis in HCT116 cells was suppressed 
downstream of FBP in the presence of FF/CAP18, and the 
cells had shifted their metabolism towards the PPP.
TCA cycle. We observed significant differences in the levels of 
metabolites of the TCA cycle. While all metabolites detected 
in this study were upregulated in HCT116 cells treated with 
10 µg/ml FF/CAP18, most metabolites of the TCA cycle were 
downregulated, with the exception of succinic acid, and then 
only in HCT116 cells treated with 40 µg/ml FF/CAP18 (Fig. 8); 
we could not confirm significant differences between HCT116 
cells treated with FF/CAP18 at 10 and 40 µg/ml in the data 
for conditioned medium (Fig. 3). Therefore, the TCA cycle in 
HCT116 cells was likely to be facilitated by the administra-
tion of FF/CAP18 at 10 µg/ml. On the other hand, inactivation 
of the TCA cycle was induced through the accumulation of 
succinic acid.
Discussion
Several studies have revealed anticancer activity of antimi-
crobial peptides, as demonstrated by oncolytic properties 
against many cancer cell types (26). However, the impact of 
antimicrobial peptides on cell metabolism is poorly under-
stood, although metabolic reprogramming is a hallmark of 
cancer cells. Our study demonstrates large-scale metabolic 
profiling of colon cancer cells after treatment with an antimi-
crobial peptide, FF/CAP18, and suggests that the apoptotic cell 
Figure 6. Metabolome data map of the purine metabolic pathway in HCT116 cells (cell-derived data) and conditioned medium (medium-derived data). Each bar 
represents the relative amount of a metabolite for non-treatment (black), treatment with FF/CAP18 at 10 µg/ml (deep grey) or 40 µg/ml (light grey) and control 
medium (white). All metabolite data are shown as the mean of triplicate samples ± standard deviation. The P-values were evaluated using Student's t-test. The 
asterisks indicate the statistical significance. *P<0.05; **P<0.01; ***P<0.001.
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death of colon cancer cells induced by FF/CAP18 is a result of 
dynamic levels of metabolites.
In the present study, PCA and HCA of large-scale meta-
bolic profiling demonstrated remarkable differences between 
non-treated HCT116 cells, cells treated with FF/CAP18 at 
10 µg/ml, and cells treated with 40 µg/ml FF/CAP18 (Figs. 4 
and 5). A great number of metabolites, including nucleotides, 
TCA cycle components, and amino acids in HCT116 cells, 
increased in HCT116 cells after treatment with FF/CAP18 
at 10 µg/ml compared with non-treated cells, indicating that 
FF/CAP18 could induce favorable metabolic conditions at 
this comparatively low concentration. On the other hand, at 
a concentration of 40 µg/ml, FF/CAP18 caused shortages of a 
number of metabolites. In previous studies, including our own, 
the cytotoxicity of various antimicrobial peptides towards 
cancer cells was reported to be dose-dependent (18,19,27). 
Thus, the results of the present study indicate that the levels of 
metabolites in cells undergoing apoptotic cell death caused by 
Figure 7. Metabolome data map of the glycolysis metabolic pathway and PPP, in HCT116 cells and in conditioned medium (medium data). Each bar represents 
the relative amount of a metabolite for non-treatment (black), treatment with FF/CAP18 at 10 µg/ml (deep grey) or 40 µg/ml (light grey) and control medium 
(white). All metabolite data are shown as the mean of triplicate samples ± standard deviation. The P-values were evaluated using Student's t-test. The asterisks 
indicate the statistical significance. *P<0.05; **P<0.01; ***P<0.001.
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antimicrobial peptides do not show unidirectional movement 
in the same way as the concentration-dependent effects previ-
ously reported.
ATP generation occurs via glycolysis rather than oxidative 
phosphorylation in cancer cells; defined as the Warburg effect, 
this is a well-established metabolic characteristic of cancer 
cells. We observed upregulation of the first three intermedi-
ates in the glycolysis pathway [glucose 1-phosphate (G1P), 
G6P, and F6P], or of only the second two intermediates (G6P 
and F6P), after treatment of FF/CAP18 at 10 or 40 µg/ml, 
respectively (Fig. 7). However, as the levels of intermediates 
downstream of FBP were not increased in this dose-dependent 
manner, conversion of F6P to FBP is the rate-limiting step of 
glycolysis, and ATP generation via glycolysis is suppressed by 
administration of FF/CAP18. When apoptosis is induced in 
cells, their metabolism is regulated by various factors, such as 
the TP53-inducible glycolysis and apoptosis regulator, which 
blocks glycolysis at the stage of conversion of F6P to FBP and 
promotes activity of the PPP (28). G1P and fructose 1-phos-
phate are used to synthesize R5P, an intermediate of the PPP, 
as an alternative route for glucose metabolism. In this study, 
the levels of PPP intermediates (Ru5P, R5P, and S7P) were 
increased in FF/CAP18-treated HCT116 cells compared with 
non-treated cells (Fig. 7). Therefore, an antimicrobial peptide, 
FF/CAP18, can shift glucose metabolism towards the PPP and 
reduce the Warburg effect, resulting in slow glycolysis.
Interestingly, intermediates in the TCA cycle were 
increased by administration of FF/CAP18 at 10 µg/ml (Fig. 8), 
indicating that HCT116 cells acquire ATP via mitochondrial 
respiration, not glycolysis, in the early stage of apoptosis 
caused by FF/CAP18 treatment. On the other hand, most of 
the TCA cycle intermediates in HCT116 cells treated with 
FF/CAP18 at 40 µg/ml were downregulated (Fig. 8). This 
inverse relationship with the concentration of FF/CAP18 
occurred in connection with the progression of apoptosis in 
treated HCT116 cells. Mitochondrial depolarization is a major 
event in the progression of apoptosis, and we confirmed that 
treatment with FF/CAP18 at 40 µg/ml induced this process in 
HCT116 cells in a previous study (19), suggesting that down-
regulation of intermediates in the TCA cycle is potentially 
caused by this alteration in mitochondrial function.
Apoptotic cell death requires ATP for the progression of 
several steps, such as caspase activation, enzymatic hydrolysis 
of macromolecules (29,30), chromatin condensation (31), bleb 
Figure 8. Metabolome data map of the TCA cycle in HCT116 cells. Each bar represents the relative amount of a metabolite for non-treatment (black), treatment 
with FF/CAP18 at 10 µg/ml (deep grey) or 40 µg/ml (light grey), and control medium (white). All metabolite data are shown as the mean of triplicate samples 
± standard deviation. The P-values were evaluated using Student's t-test. The asterisks indicate the statistical significance. *P<0.05; **P<0.01; ***P<0.001.
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formation (32), and the formation of apoptotic bodies (33). 
zamaraeva et al suggested that elevation of the ATP level 
is a prerequisite for the apoptotic cell death process (34). 
FF/CAP18 treatment at 10 µg/ml could trigger apoptosis 
of HCT116 cells via upregulation of ATP generated by 
oxidative phosphorylation rather than glycolysis. Moreover, 
increasing the FF/CAP18 concentration to 40 µg/ml induced 
late-stage apoptosis that was accompanied by a reduction 
of the ATP level via suppression of glycolysis and the TCA 
cycle and resulted in conditions wherein most metabolites 
were depleted.
Owing to screening and/or improved treatment, colorectal 
cancer mortality rates have been observed to be decreasing 
in a large number of countries (35). However, the increasing 
prevalence of obesity and decreasing levels of physical 
activity in many parts of the world continue to contribute 
to the incidence of colorectal cancer. In addition, sensitivity 
to chemotherapy and severe side effects remain unresolved 
issues. Therefore, the discovery of novel therapeutic strate-
gies for colorectal cancer is the focus of intense research 
efforts.
Antimicrobial peptides are an essential component of 
the innate immunity of many organisms, and target a wide-
range of infectious disease agents, such as fungi, protozoa 
(36), the human immunodeficiency virus and herpes viruses 
(37). Whereas antimicrobial peptides have been studied as 
antimicrobial agents, their potential as anticancer peptides 
in cancer therapy, either alone or in combination with other 
conventional drugs, has been regarded as a therapeutic 
strategy yet to be explored (26). Indeed, several recent 
studies have suggested that antimicrobial peptides possibly 
exert cytotoxic effects against colon cancer via apoptotic 
death (17,19,38). Thus, our study, approaching this issue 
from the point of view of metabolic changes, can support 
an understanding of the mechanisms of anticancer agents 
such as antimicrobial peptides, which can in turn facilitate 
the discovery of novel remedies or therapeutic strategies for 
cancer.
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